Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions

Kimberly Morishita, Jaime Guzman, Peter Chira, Eyal Muscal, Andrew Zeft, Marisa Klein-Gitelman, America G. Uribe, Leslie Abramson, Susanne M. Benseler, Anne Eberhard, Kaleo Ede, Philip J. Hashkes, Aimee O. Hersh, Gloria Higgins, Lisa F. Imundo, Lawrence Jung, Susan Kim, Daniel J. Kingsbury, Erica F. Lawson, Tzielan LeeSuzanne C. Li, Daniel J. Lovell, Thomas Mason, Deborah McCurdy, Kathleen M. O'Neil, Marilynn Punaro, Suzanne E. Ramsey, Andreas Reiff, Margalit Rosenkranz, Kenneth N. Schikler, Rosie Scuccimarri, Nora G. Singer, Anne M. Stevens, Heather Van Mater, Dawn M. Wahezi, Andrew J. White, David A. Cabral

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). Methods. We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made to the EUVAS and WGET systems to enable their application to this cohort of children. Treatment was categorized into 2 groups, "cyclophosphamide" and "no cyclophosphamide." Pearson's chi-square and Kendall's rank correlation coefficient statistical analyses were used to determine the relationship between disease severity subgroup and treatment at the time of diagnosis. Results. In total, 125 children with AAV were studied. Severity subgroup was associated with treatment group in both the EUVAS (chi-square 45.14, p < 0.001, Kendall's tau-b 0.601, p < 0.001) and WGET (chi-square 59.33, p < 0.001, Kendall's tau-b 0.689, p < 0.001) systems; however, 7 children classified by both systems as having less severe disease received CYC, and 6 children classified as having severe disease by both systems did not receive CYC. Conclusion. In this pediatric AAV cohort, the EUVAS and WGET adult severity subclassification systems had strong correlation with physician choice of treatment. However, a proportion of patients received treatment that was not concordant with their assigned severity subclass. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)2012-2020
Number of pages9
JournalJournal of Rheumatology
Volume39
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vasculitis
Cyclophosphamide
Granulomatosis with Polyangiitis
Therapeutics
Pediatrics
Antibodies
Antineutrophil Cytoplasmic Antibodies
Rheumatology
Registries

Keywords

  • Antineutrophil cytoplasmic antibodies
  • Cyclophosphamide
  • Pediatric vasculitis
  • Severity

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. / Morishita, Kimberly; Guzman, Jaime; Chira, Peter; Muscal, Eyal; Zeft, Andrew; Klein-Gitelman, Marisa; Uribe, America G.; Abramson, Leslie; Benseler, Susanne M.; Eberhard, Anne; Ede, Kaleo; Hashkes, Philip J.; Hersh, Aimee O.; Higgins, Gloria; Imundo, Lisa F.; Jung, Lawrence; Kim, Susan; Kingsbury, Daniel J.; Lawson, Erica F.; Lee, Tzielan; Li, Suzanne C.; Lovell, Daniel J.; Mason, Thomas; McCurdy, Deborah; O'Neil, Kathleen M.; Punaro, Marilynn; Ramsey, Suzanne E.; Reiff, Andreas; Rosenkranz, Margalit; Schikler, Kenneth N.; Scuccimarri, Rosie; Singer, Nora G.; Stevens, Anne M.; Van Mater, Heather; Wahezi, Dawn M.; White, Andrew J.; Cabral, David A.

In: Journal of Rheumatology, Vol. 39, No. 10, 10.2012, p. 2012-2020.

Research output: Contribution to journalArticle

Morishita, K, Guzman, J, Chira, P, Muscal, E, Zeft, A, Klein-Gitelman, M, Uribe, AG, Abramson, L, Benseler, SM, Eberhard, A, Ede, K, Hashkes, PJ, Hersh, AO, Higgins, G, Imundo, LF, Jung, L, Kim, S, Kingsbury, DJ, Lawson, EF, Lee, T, Li, SC, Lovell, DJ, Mason, T, McCurdy, D, O'Neil, KM, Punaro, M, Ramsey, SE, Reiff, A, Rosenkranz, M, Schikler, KN, Scuccimarri, R, Singer, NG, Stevens, AM, Van Mater, H, Wahezi, DM, White, AJ & Cabral, DA 2012, 'Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions', Journal of Rheumatology, vol. 39, no. 10, pp. 2012-2020. https://doi.org/10.3899/jrheum.120299
Morishita, Kimberly ; Guzman, Jaime ; Chira, Peter ; Muscal, Eyal ; Zeft, Andrew ; Klein-Gitelman, Marisa ; Uribe, America G. ; Abramson, Leslie ; Benseler, Susanne M. ; Eberhard, Anne ; Ede, Kaleo ; Hashkes, Philip J. ; Hersh, Aimee O. ; Higgins, Gloria ; Imundo, Lisa F. ; Jung, Lawrence ; Kim, Susan ; Kingsbury, Daniel J. ; Lawson, Erica F. ; Lee, Tzielan ; Li, Suzanne C. ; Lovell, Daniel J. ; Mason, Thomas ; McCurdy, Deborah ; O'Neil, Kathleen M. ; Punaro, Marilynn ; Ramsey, Suzanne E. ; Reiff, Andreas ; Rosenkranz, Margalit ; Schikler, Kenneth N. ; Scuccimarri, Rosie ; Singer, Nora G. ; Stevens, Anne M. ; Van Mater, Heather ; Wahezi, Dawn M. ; White, Andrew J. ; Cabral, David A. / Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. In: Journal of Rheumatology. 2012 ; Vol. 39, No. 10. pp. 2012-2020.
@article{39c1168689934074aaf5df8321bf4df6,
title = "Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions",
abstract = "Objective. To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). Methods. We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made to the EUVAS and WGET systems to enable their application to this cohort of children. Treatment was categorized into 2 groups, {"}cyclophosphamide{"} and {"}no cyclophosphamide.{"} Pearson's chi-square and Kendall's rank correlation coefficient statistical analyses were used to determine the relationship between disease severity subgroup and treatment at the time of diagnosis. Results. In total, 125 children with AAV were studied. Severity subgroup was associated with treatment group in both the EUVAS (chi-square 45.14, p < 0.001, Kendall's tau-b 0.601, p < 0.001) and WGET (chi-square 59.33, p < 0.001, Kendall's tau-b 0.689, p < 0.001) systems; however, 7 children classified by both systems as having less severe disease received CYC, and 6 children classified as having severe disease by both systems did not receive CYC. Conclusion. In this pediatric AAV cohort, the EUVAS and WGET adult severity subclassification systems had strong correlation with physician choice of treatment. However, a proportion of patients received treatment that was not concordant with their assigned severity subclass. The Journal of Rheumatology",
keywords = "Antineutrophil cytoplasmic antibodies, Cyclophosphamide, Pediatric vasculitis, Severity",
author = "Kimberly Morishita and Jaime Guzman and Peter Chira and Eyal Muscal and Andrew Zeft and Marisa Klein-Gitelman and Uribe, {America G.} and Leslie Abramson and Benseler, {Susanne M.} and Anne Eberhard and Kaleo Ede and Hashkes, {Philip J.} and Hersh, {Aimee O.} and Gloria Higgins and Imundo, {Lisa F.} and Lawrence Jung and Susan Kim and Kingsbury, {Daniel J.} and Lawson, {Erica F.} and Tzielan Lee and Li, {Suzanne C.} and Lovell, {Daniel J.} and Thomas Mason and Deborah McCurdy and O'Neil, {Kathleen M.} and Marilynn Punaro and Ramsey, {Suzanne E.} and Andreas Reiff and Margalit Rosenkranz and Schikler, {Kenneth N.} and Rosie Scuccimarri and Singer, {Nora G.} and Stevens, {Anne M.} and {Van Mater}, Heather and Wahezi, {Dawn M.} and White, {Andrew J.} and Cabral, {David A.}",
year = "2012",
month = "10",
doi = "10.3899/jrheum.120299",
language = "English (US)",
volume = "39",
pages = "2012--2020",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

TY - JOUR

T1 - Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions

AU - Morishita, Kimberly

AU - Guzman, Jaime

AU - Chira, Peter

AU - Muscal, Eyal

AU - Zeft, Andrew

AU - Klein-Gitelman, Marisa

AU - Uribe, America G.

AU - Abramson, Leslie

AU - Benseler, Susanne M.

AU - Eberhard, Anne

AU - Ede, Kaleo

AU - Hashkes, Philip J.

AU - Hersh, Aimee O.

AU - Higgins, Gloria

AU - Imundo, Lisa F.

AU - Jung, Lawrence

AU - Kim, Susan

AU - Kingsbury, Daniel J.

AU - Lawson, Erica F.

AU - Lee, Tzielan

AU - Li, Suzanne C.

AU - Lovell, Daniel J.

AU - Mason, Thomas

AU - McCurdy, Deborah

AU - O'Neil, Kathleen M.

AU - Punaro, Marilynn

AU - Ramsey, Suzanne E.

AU - Reiff, Andreas

AU - Rosenkranz, Margalit

AU - Schikler, Kenneth N.

AU - Scuccimarri, Rosie

AU - Singer, Nora G.

AU - Stevens, Anne M.

AU - Van Mater, Heather

AU - Wahezi, Dawn M.

AU - White, Andrew J.

AU - Cabral, David A.

PY - 2012/10

Y1 - 2012/10

N2 - Objective. To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). Methods. We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made to the EUVAS and WGET systems to enable their application to this cohort of children. Treatment was categorized into 2 groups, "cyclophosphamide" and "no cyclophosphamide." Pearson's chi-square and Kendall's rank correlation coefficient statistical analyses were used to determine the relationship between disease severity subgroup and treatment at the time of diagnosis. Results. In total, 125 children with AAV were studied. Severity subgroup was associated with treatment group in both the EUVAS (chi-square 45.14, p < 0.001, Kendall's tau-b 0.601, p < 0.001) and WGET (chi-square 59.33, p < 0.001, Kendall's tau-b 0.689, p < 0.001) systems; however, 7 children classified by both systems as having less severe disease received CYC, and 6 children classified as having severe disease by both systems did not receive CYC. Conclusion. In this pediatric AAV cohort, the EUVAS and WGET adult severity subclassification systems had strong correlation with physician choice of treatment. However, a proportion of patients received treatment that was not concordant with their assigned severity subclass. The Journal of Rheumatology

AB - Objective. To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). Methods. We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made to the EUVAS and WGET systems to enable their application to this cohort of children. Treatment was categorized into 2 groups, "cyclophosphamide" and "no cyclophosphamide." Pearson's chi-square and Kendall's rank correlation coefficient statistical analyses were used to determine the relationship between disease severity subgroup and treatment at the time of diagnosis. Results. In total, 125 children with AAV were studied. Severity subgroup was associated with treatment group in both the EUVAS (chi-square 45.14, p < 0.001, Kendall's tau-b 0.601, p < 0.001) and WGET (chi-square 59.33, p < 0.001, Kendall's tau-b 0.689, p < 0.001) systems; however, 7 children classified by both systems as having less severe disease received CYC, and 6 children classified as having severe disease by both systems did not receive CYC. Conclusion. In this pediatric AAV cohort, the EUVAS and WGET adult severity subclassification systems had strong correlation with physician choice of treatment. However, a proportion of patients received treatment that was not concordant with their assigned severity subclass. The Journal of Rheumatology

KW - Antineutrophil cytoplasmic antibodies

KW - Cyclophosphamide

KW - Pediatric vasculitis

KW - Severity

UR - http://www.scopus.com/inward/record.url?scp=84867272753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867272753&partnerID=8YFLogxK

U2 - 10.3899/jrheum.120299

DO - 10.3899/jrheum.120299

M3 - Article

C2 - 22859342

AN - SCOPUS:84867272753

VL - 39

SP - 2012

EP - 2020

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -